Is IDH mutation status associated with 18F-FDopa PET uptake?

Zaragori, Timothée; Guedj, Eric; Verger, Antoine

doi:10.1007/s12149-020-01442-1

Cited by 7 publications

(5 citation statements)

References 6 publications

(15 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The main limitations inherent to this study are that results were obtained retrospectively in a single center. In addition, our sample size was too limited for providing separate analyses according to the different molecular features of the gliomas involved in the present study, whereas it is possible that [ 18 F]-F-DOPA uptake may vary according to these features [41][42][43][44]. Furthermore, the relative low number of histologically verified cases should lead to consider with caution the very high accuracy reported in this study.…”

Section: Discussionmentioning

confidence: 88%

Use of static and dynamic [18F]-F-DOPA PET parameters for detecting patients with glioma recurrence or progression

et al. 2020

Self Cite

View full text Add to dashboard Cite

Background: Static [ 18 F]-F-DOPA PET images are currently used for identifying patients with glioma recurrence/ progression after treatment, although the additional diagnostic value of dynamic parameters remains unknown in this setting. The aim of this study was to evaluate the performances of static and dynamic [ 18 F]-F-DOPA PET parameters for detecting patients with glioma recurrence/progression as well as assess further relationships with patient outcome. Methods: Fifty-one consecutive patients who underwent an [ 18 F]-F-DOPA PET for a suspected glioma recurrence/ progression at post-resection MRI, were retrospectively included. Static parameters, including mean and maximum tumor-to-normal-brain (TBR) ratios, tumor-to-striatum (TSR) ratios, and metabolic tumor volume (MTV), as well as dynamic parameters with time-to-peak (TTP) values and curve slope, were tested for predicting the following: (1) glioma recurrence/progression at 6 months after the PET exam and (2) survival on longer follow-up. Results: All static parameters were significant predictors of glioma recurrence/progression (accuracy ≥ 94%) with all parameters also associated with mean progression-free survival (PFS) in the overall population (all p < 0.001, 29.7 vs. 0.4 months for TBR max , TSR max , and MTV). The curve slope was the sole dynamic PET predictor of glioma recurrence/ progression (accuracy = 76.5%) and was also associated with mean PFS (p < 0.001, 18.0 vs. 0.4 months). However, no additional information was provided relative to static parameters in multivariate analysis. Conclusion: Although patients with glioma recurrence/progression can be detected by both static and dynamic [ 18 F]-F-DOPA PET parameters, most of this diagnostic information can be achieved by conventional static parameters.

show abstract

Section: Discussionmentioning

confidence: 88%

Use of static and dynamic [18F]-F-DOPA PET parameters for detecting patients with glioma recurrence or progression

et al. 2020

Self Cite

View full text Add to dashboard Cite

show abstract

“…The metabolic tumor volume (MTV) and T/N failed to differentiate IDH-wildtype from IDH-mutant (p > 0.5 for both) when considering the whole population. Nevertheless, when considering only diffuse gliomas (with the exclusion of glioblastomas), MTV was higher in IDH-mutant gliomas (p = 0.002) and a trend was observed for the T/N ratio (p = 0.1) [37]. Cicone et al replied that MTV could not be considered as an uptake parameter and highlighted the trend found for T/ N in the previous study [38].…”

Section: Grading and Correlation With Histopathological Featuresmentioning

confidence: 90%

Usefulness of 18F-FDOPA PET for the management of primary brain tumors: a systematic review of the literature

et al. 2020

View full text Add to dashboard Cite

Contrast-enhanced magnetic resonance imaging is currently the standard of care in the management of primary brain tumors, although certain limitations remain. Metabolic imaging has proven useful for an increasing number of indications in oncology over the past few years, most particularly 18F-FDG PET/CT. In neuro-oncology, 18F-FDG was insufficient to clearly evaluate brain tumors. Amino-acid radiotracers such as 18F-FDOPA were then evaluated in the management of brain diseases, notably tumoral diseases. Even though European guidelines on the use of amino-acid PET in gliomas have been published, it is crucial that future studies standardize acquisition and interpretation parameters. The aim of this article was to systematically review the potential effect of this metabolic imaging technique in numerous steps of the disease: primary and recurrence diagnosis, grading, local and systemic treatment assessment, and prognosis. A total of 41 articles were included and analyzed in this review. It appears that 18F-FDOPA PET holds promise as an effective additional tool in the management of gliomas. More consistent prospective studies are still needed.

show abstract

“…3,4-dihydroxy-6-(18F) fluoro-L-phenylalanine (18F-FDOPA) is one of the most studied amino acid analog radiotracers to describe central nervous system malignancies. As mentioned, radiotracer increased amino acid transport of the tumor cells are responsible for the elevated accumulation at the malignant tissue (3,(14)(15)(16)(17)(18).…”

mentioning

confidence: 99%

Additional Value of 18F-FDOPA Amino Acid Analog Radiotracer to Irradiation Planning Process of Patients With Glioblastoma Multiforme

Sipos

László²,

Tóth

et al. 2021

Front. Oncol.

View full text Add to dashboard Cite

PurposeTo investigate the added value of 6-(18F]-fluoro-L-3,4-dihydroxyphenylalanine (FDOPA) PET to radiotherapy planning in glioblastoma multiforme (GBM).MethodsFrom September 2017 to December 2020, 17 patients with GBM received external beam radiotherapy up to 60 Gy with concurrent and adjuvant temozolamide. Target volume delineations followed the European guideline with a 2-cm safety margin clinical target volume (CTV) around the contrast-enhanced lesion+resection cavity on MRI gross tumor volume (GTV). All patients had FDOPA hybrid PET/MRI followed by PET/CT before radiotherapy planning. PET segmentation followed international recommendation: T/N 1.7 (BTV1.7) and T/N 2 (BTV2.0) SUV thresholds were used for biological target volume (BTV) delineation. For GTV-BTVs agreements, 95% of the Hausdorff distance (HD95%) from GTV to the BTVs were calculated, additionally, BTV portions outside of the GTV and coverage by the 95% isodose contours were also determined. In case of recurrence, the latest MR images were co-registered to planning CT to evaluate its location relative to BTVs and 95% isodose contours.ResultsAverage (range) GTV, BTV1.7, and BTV2.0 were 46.58 (6–182.5), 68.68 (9.6–204.1), 42.89 (3.8–147.6) cm3, respectively. HD95% from GTV were 15.5 mm (7.9–30.7 mm) and 10.5 mm (4.3–21.4 mm) for BTV1.7 and BTV2.0, respectively. Based on volumetric assessment, 58.8% (28–100%) of BTV1.7 and 45.7% of BTV2.0 (14-100%) were outside of the standard GTV, still all BTVs were encompassed by the 95% dose. All recurrences were confirmed by follow-up imaging, all occurred within PTV, with an additional outfield recurrence in a single case, which was not DOPA-positive at the beginning of treatment. Good correlation was found between the mean and median values of PET/CT and PET/MRI segmented volumes relative to corresponding brain-accumulated enhancement (r = 0.75; r = 0.72).Conclusion18FFDOPA PET resulted in substantial larger tumor volumes compared to MRI; however, its added value is unclear as vast majority of recurrences occurred within the prescribed dose level. Use of PET/CT signals proved to be feasible in the absence of direct segmentation possibilities of PET/MR in TPS. The added value of 18FFDOPA may be better exploited in the context of integrated dose escalation.

show abstract

Is IDH mutation status associated with 18F-FDopa PET uptake?

Cited by 7 publications

References 6 publications

Use of static and dynamic [18F]-F-DOPA PET parameters for detecting patients with glioma recurrence or progression

Use of static and dynamic [18F]-F-DOPA PET parameters for detecting patients with glioma recurrence or progression

Usefulness of 18F-FDOPA PET for the management of primary brain tumors: a systematic review of the literature

Additional Value of 18F-FDOPA Amino Acid Analog Radiotracer to Irradiation Planning Process of Patients With Glioblastoma Multiforme

Contact Info

Product

Resources

About